Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference

Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York.

During this oral presentation, Stanislas Veillet, CEO of Biophytis, gave an update on the company’s clinical results, presented the first results of the phase 2-3 COVA study in COVID-19-related respiratory failure and detailed the company’s next key steps.

Stanislas Veillet, CEO of Biophytis, said: “I am very happy to share the very encouraging results obtained with Sarconeos (BIO101) in the fight against COVID-19. I think this is excellent news and in the public interest at a time when COVID-19 is becoming endemic and will persist for a long time. It is the only innovative drug candidate in Europe or the United States directly targeting respiratory failure that has demonstrated clinical efficacy in hospitalized patients with hypoxemia caused by COVID-19. It could be used in combination with certain anti-viral and/or anti-inflammatory drugs, which are now part of the medical practice.”